Join Now
Pharma Sector Outperforms Amid Market Volatility
The Indian pharmaceutical sector has witnessed remarkable growth in 2025, with stocks like Glenmark Pharma, Gland Pharma, Biocon, and Laurus Labs soaring up to 79% since March.
Despite uncertainties surrounding potential US pharma tariffs, these stocks have outperformed the NSE Nifty 50 (up 15.7%) and the Nifty Pharma index (up 15%), according to a recent Business Standard report.
However, technical indicators suggest these stocks are now in overbought territory, raising questions about their sustainability.
Why Are These Stocks Overbought?
The Relative Strength Index (RSI), a key momentum indicator, shows that Glenmark Pharma, Gland Pharma, Biocon, and Laurus Labs are trading above the 70 mark, signaling overbought conditions.
This suggests that the rapid price surge may lead to a potential correction or consolidation phase. Investors are now weighing whether to hold or exit these high-flying stocks.
Key Drivers of the Rally
Several factors have fueled the impressive performance of these pharmaceutical stocks:
- Strong Financials: Companies like Glenmark Pharma reported a net profit of ₹1,047.14 crore in FY25, a significant recovery from a ₹1,830.85 crore loss in FY24 Moneycontrol.
- Innovation Pipeline: Biocon and Laurus Labs have advanced their product portfolios, focusing on biosimilars and generics, boosting investor confidence.
- Global Demand: Despite tariff threats, the global demand for affordable generics from India remains robust, supporting export-driven growth.
- Strategic Deals: Glenmark’s $700 million licensing deal with AbbVie for its cancer drug ISB 2001 has significantly driven its stock price Economic Times.
Stock Performance Overview
| Stock | 5-Month Gain | Market Cap (₹ Cr) | P/E Ratio | RSI (Daily) |
|---|---|---|---|---|
| Glenmark Pharma | 79% | 61,655.23 | 58.88 | Overbought |
| Gland Pharma | 65% | 36,000+ (est.) | 41.54 | Overbought |
| Biocon | 60% | 33,000+ (est.) | 23.29 | Overbought |
| Laurus Labs | 70% | 25,000+ (est.) | 45.00 | Overbought |
Note: Market cap and P/E ratios are approximate, based on recent data from Moneycontrol and other sources.
Should Investors Exit Now?
With RSI indicating overbought conditions, analysts suggest caution. Sudeep Shah from SBI Securities notes that Glenmark Pharma may enter a consolidation phase due to its extreme overbought status Moneycontrol. However, long-term prospects remain strong due to robust fundamentals and strategic partnerships.
Investment Strategies
- Short-Term Traders: Consider booking profits, especially for Glenmark and Laurus Labs, as technical indicators suggest a potential pullback.
- Long-Term Investors: Hold positions, given the strong growth outlook for the Indian pharma sector, supported by government initiatives like the National Policy on R&D Angel One.
- Diversify: Mitigate risks by diversifying into other pharma stocks like Sun Pharma or Cipla, which have shown resilience amid market volatility.
Risks to Watch
The threat of US tariffs on pharmaceutical imports, potentially reaching 200% as proposed by Donald Trump, could impact export-driven companies like Gland Pharma and Biocon Business Standard. Additionally, global market volatility and regulatory challenges, such as Glenmark’s recent US FDA warning letter for its Indore facility, may pose risks Screener.
Looking Ahead
The Indian pharmaceutical sector remains a high-growth area, valued at $50 billion in FY24, with exports contributing $26.5 billion Angel One. While Glenmark Pharma, Gland Pharma, Biocon, and Laurus Labs have delivered stellar returns, their overbought status calls for cautious optimism. Investors should monitor technical indicators and global developments closely.
Final Thoughts
The rally in these pharma stocks highlights their strong fundamentals and market demand. However, with RSI signaling overbought conditions, short-term corrections are possible.
For long-term investors, the sector’s growth trajectory and innovation-driven strategies make these stocks attractive. Consult a financial advisor before making investment decisions to align with your goals.